NOVOZYMES A/S: Financial statements 2016
CVR: 10007127
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
NOVOZYMES A/S (CVR 10007127) has filed annual accounts for 2016. In 2016, the company reported revenue of DKK 14,142,000,000 and a net result of DKK 3,050,000,000 compared with DKK 2,825,000,000 the year before. That is an increase of 1% compared with the year before. The profit margin was 21.6%. Equity in the 2016 report amounted to DKK 11,745,000,000. The solvency ratio was 62.9%.
- Revenue
- DKK 14,142,000,000
- Gross Profit
- DKK 8,126,000,000
- Profit/Loss
- DKK 3,050,000,000
- Equity
- DKK 11,745,000,000
- Total Assets
- DKK 18,659,000,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | 14.1B | 8.1B | 3.1B | 11.7B | - |
| 2015 | 14B | 8.1B | 2.8B | 11.6B | - |
| 2014 | 12.5B | 7.1B | 2.5B | 11.3B | - |
Official annual report
Find more companies like NOVOZYMES A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
NOVOZYMES A/S has published its interim report for the period January 1, 2016 to June 30, 2016.
NOVOZYMES A/S has published its interim report for the period January 1, 2016 to March 31, 2016.
NOVOZYMES A/S has published its annual report for 2015. Revenue came to DKK 14,002,000,000, and the net result was DKK 2,825,000,000.
As of February 24, 2016, Jørgen Buhl Rasmussen has joined the board of directors of NOVOZYMES A/S.
As of February 24, 2016, Agnete Raaschou-Nielsen has joined the board of directors of NOVOZYMES A/S.
As of February 24, 2016, Lena Marie Olving has left the board of directors of NOVOZYMES A/S.
As of February 23, 2016, Jørgen Buhl Rasmussen has left the board of directors of NOVOZYMES A/S.
As of February 23, 2016, Agnete Raaschou-Nielsen has left the board of directors of NOVOZYMES A/S.
As of February 8, 2016, Per Falholt has stepped down as director of NOVOZYMES A/S.
As of February 8, 2016, Thomas Geza Solyom Nagy has stepped down as director of NOVOZYMES A/S.
About NOVOZYMES A/S
NOVOZYMES A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2000. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of Ester Baiget Arnau and Rainer Chapour Lehmann. The board consists of Cornelis de Jong (chair), Heine Dalsgaard, Frederikke Rose Spenner and Kasim Kutay. The company is owned by Novo Holdings A/S and BlackRock, Inc.. The company has 3,508 employees (2026). In 2025, the company reported revenue of EUR 4,157,600,000 and a net result of EUR 583,600,000 compared with EUR 305,800,000 the year before. Equity in the 2025 report amounted to EUR 10,855,200,000.